W. L. Gore & Associates, Inc. REVISE Study Receives Conditional Approval from FDA

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--Conditional approval to proceed with the Gore REVISE (VasculaR AccEss ReVision with GORE VIABAHN® EndoproSthesis vs PercutanEous Transluminal Angioplasty) Study was announced today by W. L. Gore & Associates (Gore). The Gore REVISE Study is a randomized, multi-center clinical trial intended to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to revise arterio-venous grafts at the venous anastomosis in hemodialysis patients. The study will randomize patients to the GORE VIABAHN® Endoprosthesis and to percutaneous transluminal angioplasty (PTA).

MORE ON THIS TOPIC